29
Participants
Start Date
October 5, 2012
Primary Completion Date
April 26, 2016
Study Completion Date
January 9, 2020
Temsirolimus
10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
Sorafenib:
200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
Robert H Lurie Comprehensive Cancer Center, Chicago
University of California, San Francisco, San Francisco
Collaborators (1)
Robert H. Lurie Cancer Center
OTHER
Pfizer
INDUSTRY
University of California, San Francisco
OTHER